In the United States, the company has been given approval and go signal by the Food and Drug Administration to start manufacturing and commercializing their HORIZANT (gabapentin enacarbil) Extended-Release Tablets, which are used to treat severe primary restless legs syndrome. In Japan, they also have the license to market their REGNITE for the treatment of moderate to severe primary RLS. The license was issued by the Japanese Ministry of Health, Labor and Welfare.
Through the strategic partnership of Xenoport, Inc. with other pharmaceutical companies, it further advances the discovery of novelty therapeutics for neurological diseases, including that for Parkinson’s disease. It was in 1999 that the company commences its operations.